Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 1, 2026, 11:23 AM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1249–1272 of 1,468 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Infection Control Clear all
Completed Early Phase 1 Interventional Accepts healthy volunteers

A Novel Probiotic-antibiotic Combination to Prevent Recurrent Urinary Tract Infections

NCT06149676
View directory record Official record
Conditions
Recurrent Uti
Interventions
Saccharomyces Boulardii 250 MG [Florastor]
Drug
Lead sponsor
Ann & Robert H Lurie Children's Hospital of Chicago
Other
Eligibility
2 Years to 17 Years
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Nov 1, 2026, 11:23 AM EST
Completed Phase 2 Interventional Results available

A Randomized Placebo-controlled Safety and Dose-finding Study for the Use of the IL-6 Inhibitor Clazakizumab in Patients With Life-threatening COVID-19 Infection

NCT04343989
View directory record Official record
Conditions
COVID-19
Interventions
Clazakizumab 25 mg, Clazakizumab 12.5 mg, Placebo
Drug · Other
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
178 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
3
States / cities
Phoenix, Arizona • Baltimore, Maryland • New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 14, 2022 · Synced Nov 1, 2026, 11:23 AM EST
Terminated Phase 3 Interventional

Moxifloxacin in Preventing Bacterial Infections in Patients Who Have Undergone Donor Stem Cell Transplant

NCT00324324
View directory record Official record
Conditions
Breast Cancer, Chronic Myeloproliferative Disorders, Gestational Trophoblastic Tumor, Infection, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Neuroblastoma, Ovarian Cancer, Testicular Germ Cell Tumor
Interventions
moxifloxacin hydrochloride, Placebo
Drug
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years to 120 Years
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated May 9, 2017 · Synced Nov 1, 2026, 11:23 AM EST
Completed No phase listed Observational

Immune Correlates of Cardiac Structure and Function

NCT05328713
View directory record Official record
Conditions
Perinatal HIV Infection, Cardiac Fibrosis, Cardiac Inflammation
Interventions
Cardiac MRI
Diagnostic Test
Lead sponsor
Duke University
Other
Eligibility
20 Years to 45 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 21, 2024 · Synced Nov 1, 2026, 11:23 AM EST
Completed Phase 2 Interventional

The Safety and Effectiveness of Zidovudine in the Treatment of HIV-Infected Children With Mild to Moderate Symptoms

NCT00000990
View directory record Official record
Conditions
HIV Infections
Interventions
Zidovudine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
3 Months to 12 Years
Enrollment
224 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1992
U.S. locations
33
States / cities
Downey, California • Long Beach, California • Los Angeles, California + 18 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2021 · Synced Nov 1, 2026, 11:23 AM EST
Completed Phase 3 Interventional

Glutamine Supplementation to Prevent Death or Infection in Extremely Premature Infants

NCT00005775
View directory record Official record
Conditions
Infant, Newborn, Infant, Low Birth Weight, Infant, Small for Gestational Age, Infant, Premature, Sepsis
Interventions
Glutamine, Placebo
Drug
Lead sponsor
NICHD Neonatal Research Network
Network
Eligibility
Up to 72 Hours
Enrollment
1,433 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2001
U.S. locations
15
States / cities
Birmingham, Alabama • Palo Alto, California • San Diego, California + 12 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2015 · Synced Nov 1, 2026, 11:23 AM EST
Completed Phase 2Phase 3 Interventional Results available

Posoleucel (ALVR105, Formerly Viralym-M) for Multi-Virus Prevention in Patients Post-Allogeneic Hematopoietic Cell Transplant

NCT04693637
View directory record Official record
Conditions
Adenovirus Infection, BK Virus Infection, Cytomegalovirus Infections, Epstein-Barr Virus Infections, Human Herpes Virus-6 Infection, JC Virus Infection
Interventions
Posoleucel (ALVR105)
Biological
Lead sponsor
AlloVir
Industry
Eligibility
1 Year and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
16
States / cities
Birmingham, Alabama • Duarte, California • San Francisco, California + 12 more
Source: ClinicalTrials.gov public record
Updated May 9, 2024 · Synced Nov 1, 2026, 11:23 AM EST
Terminated Not applicable Interventional

Safety and Efficacy Study of Ethanol Locking to Prevent Central Line Infection in Premature Neonates

NCT01365312
View directory record Official record
Conditions
Infection Associated With Catheter, Bacteremia, Sepsis
Interventions
Ethanol lock, Heparinized saline
Drug
Lead sponsor
East Carolina University
Other
Eligibility
Up to 32 Weeks
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2010
U.S. locations
1
States / cities
Greenville, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 3, 2014 · Synced Nov 1, 2026, 11:23 AM EST
Not listed Not applicable Interventional Accepts healthy volunteers

Capacity Builders Inc. Navajo Youth Builders Personal Responsibility Education Innovation Strategies Project

NCT04180358
View directory record Official record
Conditions
Sexual Abstinence, Responsible Sex
Interventions
Native STAND, Regular Health/Physical Education Curriculum
Behavioral
Lead sponsor
Capacity Builders Inc.
Other
Eligibility
14 Years to 18 Years
Enrollment
834 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2021
U.S. locations
1
States / cities
Farmington, New Mexico
Source: ClinicalTrials.gov public record
Updated Nov 27, 2019 · Synced Nov 1, 2026, 11:23 AM EST
Terminated Phase 2 Interventional Results available

A Trial of Perioperative CV301 Vaccination in Combination With Nivolumab and Systemic Chemotherapy for Metastatic CRC

NCT03547999
View directory record Official record
Conditions
Metastatic Colorectal Cancer
Interventions
mFOLFOX6, MVA-BN-CV301, FPV-CV301, Nivolumab
Drug · Biological
Lead sponsor
Patrick Boland
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
7
States / cities
Duarte, California • Miami, Florida • Westwood, Kansas + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2025 · Synced Nov 1, 2026, 11:23 AM EST
Completed Not applicable Interventional Results available

Air Barrier System for the Prevention of Surgical Site Infection

NCT01610271
View directory record Official record
Conditions
Surgical Site Infection
Interventions
Air Barrier System
Device
Lead sponsor
Nimbic Systems, LLC
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 3, 2019 · Synced Nov 1, 2026, 11:23 AM EST
Completed Phase 2 Interventional Results available

Urinary Track Infection Prevention After Urogynecological Surgery

NCT03818321
View directory record Official record
Conditions
Urinary Tract Infections, Urinary Retention Postoperative, Pelvic Organ Prolapse
Interventions
Methenamine Hippurate 1 g tablet, Placebo tablet
Drug
Lead sponsor
TriHealth Inc.
Other
Eligibility
18 Years to 80 Years · Female only
Enrollment
185 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 14, 2022 · Synced Nov 1, 2026, 11:23 AM EST
Not yet recruiting No phase listed Observational

Understanding the Long-term Impact of COVID-19 in Adults

NCT07498504
View directory record Official record
Conditions
Long COVID, Long Covid19
Interventions
Not listed
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 100 Years
Enrollment
5,205 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 27, 2026 · Synced Nov 1, 2026, 11:23 AM EST
Terminated Phase 3 Interventional Results available

Dexamethasone Versus Ketorolac Injection for the Treatment of Local Inflammatory Hand and Upper Extremity Disorders

NCT02266433
View directory record Official record
Conditions
DeQuervains Tenosynovitis, Lateral Epicondylitis, Tennis Elbow, Trigger Finger, Tenosynovitis, Inflammatory Disease
Interventions
Ketorolac, Dexamethasone
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
245 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 2, 2020 · Synced Nov 1, 2026, 11:23 AM EST
Completed Phase 2 Interventional Results available

A Dose Ranging Study Of PF-00868554 In Combination With PEGASYS And COPEGUS In Patients With Chronic Hepatitis C Genotype 1 Infection

NCT00720434
View directory record Official record
Conditions
Hepatitis C
Interventions
PF-00868554, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 65 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
9
States / cities
La Jolla, California • San Francisco, California • Orlando, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2013 · Synced Nov 1, 2026, 11:23 AM EST
Completed Phase 3 Interventional Results available

Remdesivir for Severely Ill Inpatients With COVID-19 (An ACTIV-3b/TESICO Treatment Trial)

NCT06729593
View directory record Official record
Conditions
Covid19
Interventions
Remdesivir, Remdesivir Placebo, Corticosteroid
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
40
States / cities
Tucson, Arizona • Fresno, California • Loma Linda, California + 28 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2025 · Synced Nov 1, 2026, 11:23 AM EST
Terminated Phase 1 Interventional Accepts healthy volunteers Results available

A Phase 1 Trial of PfSPZ Vaccine in Healthy Adults to Determine Safety, Tolerability and Efficacy Against Heterologous CHMI

NCT05604521
View directory record Official record
Conditions
Malaria, Malaria,Falciparum
Interventions
PfSPZ Vaccine, PfSPZ Challenge (7G8), Normal Saline
Biological · Other
Lead sponsor
Sanaria Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 25, 2024 · Synced Nov 1, 2026, 11:23 AM EST
Recruiting Not applicable Interventional Accepts healthy volunteers

Is Methenamine Prophylaxis for Urinary Tract Infection After Midurethral Sling as Effective as Antibiotic Prophylaxis?

NCT06810687
View directory record Official record
Conditions
Urinary Tract Infection (Diagnosis)
Interventions
Methenamine Hippurate 1g BD, Antibiotic prophylaxis
Drug · Other
Lead sponsor
Atlantic Health System
Other
Eligibility
18 Years to 100 Years · Female only
Enrollment
190 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2028
U.S. locations
1
States / cities
Morristown, New Jersey
Source: ClinicalTrials.gov public record
Updated Feb 7, 2025 · Synced Nov 1, 2026, 11:23 AM EST
Completed Not applicable Interventional Accepts healthy volunteers Results available

Effect of Expanding (Gloving) Barrier Precautions for Reducing Clostridium Difficile Acquisition (and Infection) in VA

NCT04036058
View directory record Official record
Conditions
Clostridium Difficile
Interventions
Universal gloving
Other
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
780 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
6
States / cities
Washington D.C., District of Columbia • Hines, Illinois • The Bronx, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 11, 2025 · Synced Nov 1, 2026, 11:23 AM EST
Enrolling by invitation Phase 3 Interventional

ODYSSEY: A Study to Investigate the Efficacy of Tradipitant in Treating Severe or Critical COVID-19 Infection

NCT04326426
View directory record Official record
Conditions
Coronavirus Infection
Interventions
Tradipitant, Placebo
Drug
Lead sponsor
Vanda Pharmaceuticals
Industry
Eligibility
18 Years to 90 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 20, 2020 · Synced Nov 1, 2026, 11:23 AM EST
Enrolling by invitation Not applicable Interventional

Reducing Overuse of Antibiotics at Discharge Home

NCT06106204
View directory record Official record
Conditions
Pneumonia, Urinary Tract Infection, Antibiotic Stewardship, Care Transition
Interventions
ROAD Home Intervention
Other
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jan 14, 2026 · Synced Nov 1, 2026, 11:23 AM EST
Active, not recruiting Phase 3 Interventional Accepts healthy volunteers

A Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of VAX-31 With Influenza Vaccine in Adults ≥ 50 Years of Age

NCT07365826
View directory record Official record
Conditions
Pneumococcal Vaccines
Interventions
31-valent pneumococcal conjugate vaccine, Seasonal Influenza Vaccine (SIV) (Flublok), Placebo
Biological
Lead sponsor
Vaxcyte, Inc.
Industry
Eligibility
50 Years and older
Enrollment
1,390 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
25
States / cities
Phoenix, Arizona • Fort Collins, Colorado • DeLand, Florida + 22 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Nov 1, 2026, 11:23 AM EST
Completed Phase 2 Interventional Accepts healthy volunteers

Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity Study in VLBW Neonates of BSYX-A110

NCT00631800
View directory record Official record
Conditions
Staphylococcal Sepsis
Interventions
Pagibaximab (formerly BSYX-A110)
Drug
Lead sponsor
Biosynexus Incorporated
Industry
Eligibility
48 Hours to 120 Hours
Enrollment
88 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2004
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 10, 2008 · Synced Nov 1, 2026, 11:23 AM EST
Recruiting Not applicable Interventional

Prophylaxis With Direct-acting Antivirals for Kidney Transplantation From HCV-Infected Donors to Uninfected Recipients

NCT05653232
View directory record Official record
Conditions
HCV
Interventions
Prophylaxis (P2W), Transmit and Treat (T&T)
Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
9
States / cities
La Jolla, California • Loma Linda, California • Baltimore, Maryland + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2026 · Synced Nov 1, 2026, 11:23 AM EST